End-of-day quote
Shenzhen S.E.
06:00:00 2024-04-25 pm EDT
|
5-day change
|
1st Jan Change
|
31.33
CNY
|
+3.23%
|
|
+10.71%
|
-22.81%
|
Fiscal Period: December |
2018
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Capitalization
1 |
11,839
|
20,310
|
14,062
|
12,971
|
12,971
|
-
|
Enterprise Value (EV)
1 |
11,839
|
20,310
|
14,062
|
16,805
|
12,971
|
12,971
|
P/E ratio
|
31.8
x
|
30.3
x
|
155
x
|
290
x
|
26.1
x
|
19.5
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
15.3
x
|
10.2
x
|
-
|
11
x
|
6.47
x
|
4.93
x
|
EV / Revenue
|
15.3
x
|
10.2
x
|
-
|
11
x
|
6.47
x
|
4.93
x
|
EV / EBITDA
|
-
|
22.6
x
|
-
|
58.4
x
|
18.9
x
|
14.3
x
|
EV / FCF
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
8.26
x
|
8.08
x
|
-
|
5.49
x
|
3.61
x
|
3.24
x
|
Nbr of stocks (in thousands)
|
400,100
|
401,232
|
413,232
|
414,020
|
414,020
|
-
|
Reference price
2 |
29.59
|
50.62
|
34.03
|
31.33
|
31.33
|
31.33
|
Announcement Date
|
1/30/19
|
3/29/22
|
4/28/23
|
3/29/24
|
-
|
-
|
Fiscal Period: December |
2018
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net sales
1 |
772.5
|
1,994
|
-
|
1,533
|
2,004
|
2,633
|
EBITDA
1 |
-
|
897.8
|
-
|
287.5
|
686
|
904
|
EBIT
1 |
440.8
|
822
|
-
|
103.2
|
704
|
935
|
Operating Margin
|
57.06%
|
41.22%
|
-
|
6.73%
|
35.13%
|
35.51%
|
Earnings before Tax (EBT)
1 |
440.7
|
802.5
|
-
|
99.74
|
695
|
929
|
Net income
1 |
371.5
|
673.3
|
-
|
58.97
|
498
|
667
|
Net margin
|
48.09%
|
33.76%
|
-
|
3.85%
|
24.85%
|
25.33%
|
EPS
2 |
0.9300
|
1.670
|
0.2200
|
0.1400
|
1.200
|
1.610
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
1/30/19
|
3/29/22
|
4/28/23
|
3/29/24
|
-
|
-
|
Fiscal Period: December |
2024 Q1
|
---|
Net sales
1 |
469
|
EBITDA
|
-
|
EBIT
|
-
|
Operating Margin
|
-
|
Earnings before Tax (EBT)
|
-
|
Net income
1 |
75
|
Net margin
|
15.99%
|
EPS
|
-
|
Dividend per Share
|
-
|
Announcement Date
|
-
|
Fiscal Period: December |
2018
|
2021
|
2023
|
2024
|
2025
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
28.1%
|
26.7%
|
1.95%
|
13.9%
|
16.6%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
4.4%
|
10.4%
|
11.6%
|
Assets
1 |
-
|
-
|
4,159
|
4,788
|
5,750
|
Book Value Per Share
2 |
3.580
|
6.260
|
7.390
|
8.670
|
9.680
|
Cash Flow per Share
|
0.8300
|
1.670
|
-
|
-
|
-
|
Capex
1 |
-
|
-
|
304
|
250
|
230
|
Capex / Sales
|
-
|
-
|
19.84%
|
12.48%
|
8.74%
|
Announcement Date
|
1/30/19
|
3/29/22
|
3/29/24
|
-
|
-
|
Last Close Price
31.33
CNY Average target price
48
CNY Spread / Average Target +53.21% Consensus |
1st Jan change
|
Capi.
|
---|
| -22.81% | 1.79B | | +12.07% | 128B | | -9.04% | 10.65B | | +0.91% | 8.82B | | +16.72% | 7.19B | | +25.15% | 4.99B | | +7.17% | 3.4B | | -1.36% | 3.03B | | -8.73% | 2.14B | | -10.15% | 2B |
Medical Devices & Implants
|